Scott Woodman

6PUBLICATIONS
97CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 10, 2025
Cancer Testis Antigen Expression Correlates With Immune Activation and Survival in Small Bowel Neuroendocrine Tumors.

Reed I Ayabe, Y David Seo, Brenda Melendez

|Apr 27, 2025
Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial.

Shiao-Pei Weathers, Xiqi Li, Haifeng Zhu

|Feb 28, 2025
Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal.

Van K Morris, Suyu Liu, Kangyu Lin

|May 06, 2024
Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma.

Nicholas J Hornstein, Mohammad A Zeineddine, Betul B Gunes

|Sep 27, 2022
Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma.

Andrew W Hahn, Ashley V Menk, Dayana B Rivadeneira

|Jul 09, 2022
Multi-modal molecular programs regulate melanoma cell state.

Miles C Andrews, Junna Oba, Chang-Jiun Wu

Pageof 1

Frequent Collaborators

4 joint publications

P Andrew Futreal

4 joint publications

Mark Knafl

3 joint publications

Daniel M Halperin

3 joint publications

Alexander J Lazar